Stock Ratings / Health Care / KPRX / dividends

IMRN (47) XCUR (32) CNSP (43) LEXX (34) ⌘ Pro Terminal →

Kiora Pharmaceuticals Inc. (KPRX) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is KPRX trading relative to its 50-day, 200-day, and 52-week technical levels?

KPRX last traded at $1.56 (-11.36% on volume of 100,696 shares), positioning the stock -36.59% below its 50-day simple moving average ($2.46) and -35.27% below its 200-day simple moving average ($2.41). Across its 52-week range of $1.55 to $2.91, KPRX sits at the 0.7% percentile with a 14-day RSI of 25.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.36 to $1.76).

Q: Does KPRX pay a dividend and is it safe?

Kiora Pharmaceuticals Inc. (KPRX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$1.56 -11.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.53

Kiora Pharmaceuticals Inc. (KPRX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $6.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KPRX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.56 (-11.36% 1D, market cap $6.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KPRX ranks #814 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KPRX compare to IMRN and XCUR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KPRX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMRN (Immuron Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $7.1M) and XCUR (Exicure Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $6.6M). Among the 5-stock peer group, KPRX leads on earnings multiple (N/A) while KPRX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KPRX?

▼

Per KPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001372514), Kiora Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$10.8K in net income, and -$10.1M in free cash flow against $24.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.53 (-2.23%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KPRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY KPRX SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 25.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.47-5.7% Next Q

Q2 (-2Q)

Grade E$2.33-1.3% Next Q

Q3 (-1Q)

Grade E$2.30-32.2% Next Q

Current

Grade E$1.56-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KPRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KPRX currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.46) and Max Pain ($1.64) forces dealer call-delta covering toward $3.06.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KPRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KPRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KPRX)

✓Walkthrough of KPRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KPRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.58%🛡️ HOLDING TREND SUPPORT

2026-11-03O $1.76H $1.76L $1.56C $1.56VOL 100.7K

RES: $2.92SUP: $1.53SMA50: $2.46SMA200: $2.41

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KPRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KPRX Butterfly Map → + Track KPRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KPRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KPRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KPRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KPRX)

Health Care Rank #814 of 1016 ⚔️ IMRN vs KPRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KPRX vs. IMRN, XCUR, CNSP, LEXX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kiora Pharmaceuticals Inc. (KPRX) ranks #814 by composite RQD confidence (30/100, grade E) and #921 by equity capitalization ($6.9M). Within this direct 5-issuer industry benchmark cohort, KPRX leads on earnings valuation at N/A trailing P/E, while KPRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMRN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with KPRX at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KPRX ACTIVE Kiora Pharmaceuticals Inc.	E	30/100	—	—	-35.0%	-11.36%	$6.9M	Benchmark Subject
IMRN Immuron Limited	D	47/100	—	—	—	-4.60%	$7.1M	/imrn-vs-kprx →
XCUR Exicure Inc.	E	32/100	—	—	-35.0%	+8.05%	$6.6M	/xcur-vs-kprx →
CNSP CNS Pharmaceuticals Inc.	D-	43/100	—	—	-35.0%	+4.82%	$7.3M	/cnsp-vs-kprx →
LEXX Lexaria Bioscience Corp.	E	34/100	—	96.0%	-35.0%	-7.43%	$7.4M	/lexx-vs-kprx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001372514

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kiora Pharmaceuticals Inc. (KPRX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $16.0M ) , GAAP net income of -$10.8K, operating cash flow of -$10.0M, and free cash flow of -$10.1M (-217.8% YoY). On the balance sheet, KPRX closed FY2025 with $24.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$10.8K	-$10.0M	-$10.1M	$24.3M	—
FY2024 (FY)	2024-12-31	$16.0M	$3.6K	$8.6M	$8.6M	$36.5M	—
FY2023 (FY)	2023-12-31	$0	-$12.5K	-$9.6M	-$9.6M	—	—

3. KPRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KPRX compare to IMRN and XCUR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KPRX?

Where is KPRX trading relative to its 50-day, 200-day, and 52-week technical levels?

KPRX last traded at $1.56 (-11.36% on volume of 100,696 shares), positioning the stock -36.59% below its 50-day simple moving average ($2.46) and -35.27% below its 200-day simple moving average ($2.41). Across its 52-week range of $1.55 to $2.91, KPRX sits at the 0.7% percentile with a 14-day RSI of 25.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.36 to $1.76).

KPRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does KPRX pay a dividend and is it safe?

Kiora Pharmaceuticals Inc. (KPRX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: KPRX RQD Cockpit KPRX 12M Forecast KPRX Earnings & Move KPRX Dividends & DRIP KPRX Insiders & 13F KPRX Whale Options KPRX Profit Sankey KPRX News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

KPRX — Kiora Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:52:25Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, KPRX scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the cash engine and the smart-money signals, which together indicate that the business is not currently generating cash returns and that informed capital is not showing conviction. The balance-sheet pillar is the strongest of the five but still reflects a weak Piotroski reading. Macro fit is neutral-to-modest given a beta of 1.0. The rating points to downside-risk considerations rather than upside drivers. Any upside case would need to rest on catalysts outside the reported fundamentals, which the source data does not quantify.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-12.8M	$-0.0M	N/A	$-10.1M	$8.7M	N/A
FY 2024	$16.0M	$4.5M	$0.0M	N/A	$8.6M	$3.8M	N/A
FY 2023	$0.0M	$-12.6M	$-0.0M	N/A	$-9.6M	N/A	N/A

Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, with Debt/Equity at 0.5. The FY 2024 period is the only one showing positive operating income and free cash flow, while FY 2025 returned to an operating loss of $-12.8M. The reported debt figures are N/A across all periods, so the balance-sheet leverage picture is limited to the Debt/Equity ratio cited in the RQD rating.

Open Questions

What is the company's revenue model and commercial product base, given that the source reports $0.0M revenue for FY 2025 and FY 2023?
What explains the FY 2024 revenue of $16.0M and its absence in subsequent periods?
Which figures are correct for market capitalization and price, given the conflicts between the profile ($0.0B), market data ($7.8M; $1.76), and headline ($2.34)?
What are the debt and cash positions across all periods, since debt is N/A and cash is missing for FY 2023?
What are the terms, counterparties, and remaining milestones of the in-licensed calpain inhibitor program?

KPRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kiora Pharmaceuticals Inc. (KPRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KPRX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 18h ago

Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan

Yahoo Finance report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 21h ago

Maxim Group Maintains Kiora Pharmaceuticals(KPRX.US) With Buy Rating, Maintains Target Price $12

Moomoo report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

KPRX Q3'26 Earnings: revenue estimate is 0 USD

TradingView report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Kiora Pharmaceuticals Q3 2026 Earnings Date and Estimates

MarketBeat report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Kiora Pharmaceuticals (KPRX) Slips 0.43% to $2.34 as Shares Test Lower End of Recent Range - Charm Flow

https://www.siam.in/ report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST www.dars.gov.et • 1d ago

KPRX Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.34 Per Share Beats Consensus - New Analyst Coverage

www.dars.gov.et report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Kiora Pharmaceuticals, Inc. (KPRX) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Kiora Pharmaceuticals, Inc. Stock Price Today | KPRX Live Chart & News

Traders Union report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KPRX Bull vs. Bear Conversation Board — What's Your Call at $1.56?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KPRX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.55 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is KPRX (E • RQD 30/100) a Buy at $1.76?

Welcome to the KPRX (Kiora Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.32 (-25.0%)

Spot @ $1.76

Pump the brakes on KPRX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on KPRX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Kiora Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.08 (+18.2%)

Spot @ $1.76

KPRX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on KPRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.76 (52-wk range $1.55 - $2.91), any beat on forward guidance forces shorts and underweight funds to chase.